COUNCIL OF THE DISTRICT OF COLUMBIA
OFFICE OF COUNCILMEMBER BROOKE PINTO
THE JOHN A. WILSON BUILDING
1350 PENNSYLVANIA AVENUE, N.W., SUITE 106
WASHINGTON, D.C. 20004
September 18, 2023
Nyasha Smith, Secretary
Council of the District of Columbia
1350 Pennsylvania Avenue, N.W.
Washington, DC 20004
Dear Secretary Smith,
Today, I, along with Councilmembers Christina Henderson, Robert White, Charles Allen,
Vincent Gray, Matt Frumin, Janeese Lewis George, and Anita Bonds am introducing the
“Transgender and Gender-Diverse Mortality and Fatality Review Committee Establishment Act
of 2023.” Please find enclosed a signed copy of the legislation.
With the death of Jasmine “Star” Mack on January 7, 2023, the District marked a grim milestone:
the first transgender person in the country to be violently killed in 2023 lived and died in D.C.
1
Despite transgender and gender-diverse people only making up approximately 1.6 million of the
population
2
in the United States, mortality, fatality, and morbidity trends for this group compared
to cisgender people are disproportionately high.
3
Although data are limited, some studies suggest
that transgender people are “twice as likely to die as cisgender people” due to “heart disease, lung
cancer, HIV-related illness and suicide,” with trans women being “two times as likely to die”
compared to cis men and “three times as likely” compared to cis women.
4
Trans women in
particular are disproportionately vulnerable to the aforementioned risks, as well as to violence and
murder, with one in four trans women likely to be victimized by a hate-related crime.
5
Meanwhile,
trans women of color are even more overrepresented as victims of violence and murder.
6
1
Casey Parks and Jenna Portnoy, Transgender woman killed in in D.C. ‘just wanted a chance at life’, Washington
Post (Jan. 15, 2023), available here.
2
Williams Institute, Transgender People, available here. “Trans” covers any and all individuals whose gender identity
or expression differs from the sex/gender assigned at birth, irrespective of medical, hormonal, or surgical intervention.
“Mortality” here denotes death by natural or accidental causes; “fatality” denotes death by homicide or suicide. See
also LGBT Mortality Project, Resources, available here.
3
Cf. Sarah S. Jackson, et al. Analysis of Mortality Among Transgender and Gender Diverse Adults in England,
JAMA Netw Open (Jan. 3, 2023); 6(1):e2253687. doi: 10.1001/jamanetworkopen.2022.53687. PMID: 36716027;
PMCID: PMC9887492, available here.
4
Robert Hart, Transgender People Twice As Likely To Die As Cisgender People, Study Finds, Forbes (Sep. 2, 2021),
available here.
5
Cf. Williams Institute, Gender Identity Disparities in Criminal Victimization, National Crime Victimization Survey,
2017-2018, available here. Hannah Schoenbaum, Report says at least 32 transgender people were killed in the U.S.
in 2022, PBS News Hour (Nov. 16, 2022), available here.
6
Harvard Civil Rights-Civil Liberties Law Review, America’s War on Black Trans Women (Sep. 23, 2020), available
here; Faith Karimi, Deadly attacks on Black trans women are going up, advocacy group says, CNN (Jun. 13, 2021),
Transgender fatalities from violence have continued to rise in recent years, making the need for
policy intervention especially urgent.
7
All of this suggests that trans and gender-diverse people may face particular vulnerabilities that
cisgender people do not. There is thus an urgent need for more information about trans and
gender-diverse people’s lives and deaths, so that the District can properly support health
outcomes for this constituency.
To facilitate this important work, this legislation would establish a Transgender and Gender-
Diverse Mortality and Fatality Review Committee. This Committee would complement the
District’s existing mortality and fatality review committees administered by the Office of the Chief
Medical Examiner (“OCME”). The Transgender and Gender-Diverse Mortality and Fatality
Review Committee would consist of representatives from OCME and other relevant District
agencies; representatives from District hospitals, transgender and gender-diverse advocacy
organizations, housing organizations, healthcare providers, researchers from a college or
university within the District conducting research in this area, and social workers specializing in
transgender and gender-diverse issues. The Committee would be tasked with identifying and
characterizing the scope and nature of transgender mortalities and fatalities; recording trends;
conducting retrospective socioeconomic analyses; and working to develop policy
recommendations.
The establishment of this Committee will continue the District’s leading role in LGBTQIA+
advocacy and legislation. The Committee will be the first entity of its kind in the United States. It
will contribute important data and analysis and provide important resources for the National Center
for Fatality Review and Prevention and for transgender and gender-diverse people across the
country and inform future strategies and interventions to drive down the disparate outcomes we
are currently seeing with our transgender and gender-diverse residents.
Should you have any questions about this legislation, please contact Michael Porcello, Committee
Director for the Committee on the Judiciary and Public Safety, at mporcello@dccouncil.gov.
Thank you,
Brooke Pinto
available here; Trudy Ring, Here Are the 57 Trans Americans Killed in 2021, Advocate (May 5, 2022), available here;
Laken Brooks, 2021 Has Been A Deadly Year for Transgender People (Nov. 14, 2021), available here.
7
Human Rights Campaign, Fatal Violence Against the Transgender and Gender Non-Conforming Community in
2021, available here; Orion Rummler and Kate Sosin, 2021 is now the deadliest year on record for transgender
people, PBS News Hour (Nov. 18, 2021), available here. 1
___________________________ ______________________________ 1
Councilmember Robert C. White, Jr. Councilmember Brooke Pinto 2
3
4
___________________________ ______________________________ 5
Councilmember Anita Bonds Councilmember Christina Henderson 6
7
8
______________________________ ______________________________ 9
Councilmember Vincent C. Gray Councilmember Charles Allen 10
11
12
______________________________ ______________________________ 13
Councilmember Janeese Lewis George Councilmember Matthew Frumin 14
15
16
17
A BILL 18
__________ 19
20
21
IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 22
23
24
__________________ 25
26
27
To establish a Transgender and Gender-Diverse Mortality and Fatality Review Committee within 28
the Office of the Chief Medical Examiner to determine the causes associated with 29
transgender and gender diverse mortalities and fatalities of District residents and those 30
that occur in the District, to identify and characterize the scope and nature of transgender 31
and gender-diverse mortalities and fatalities, to describe and record any trends, data, or 32
patterns that are observed surrounding transgender and gender-diverse mortalities and 33
fatalities, to create a strategic framework for improving transgender and gender-diverse 34
health outcomes for racial and ethnic minorities in the District, to recommend training to 35
improve the identification, investigation, and prevention of transgender and gender-36
diverse mortalities and fatalities, and to make publicly available an annual report of its 37
findings, recommendations, and steps taken to evaluate implementation of past 38
recommendations. 39
40
BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this 41
act may be cited as the “Transgender and Gender-Diverse Mortality and Fatality Review 42
Committee Establishment Amendment Act of 2023”. 43 2
Sec. 2. Definitions. 44
For purposes of this act, the term: 45
(1) “Cisgender” shall have the same meaning as provided in D.C. Official Code § 46
1-607.61(1). 47
(2) "Committee" means the Transgender and Gender-Diverse Mortality and 48
Fatality Review Committee. 49
(3) “Documentation memorializing transgender or gender-diverse status” means 50
documentation that memorialize a decedent’s gender transition, and may include: 51
(A) A written statement by the decedent self-identifying as transgender, 52
gender-diverse, or not cisgender; 53
(B) Documentation of a change to the decedent's gender marker on a 54
certificate of birth, driver's license or state identification card, social security record, or passport; 55
(C) A court order approving a name or gender change; or 56
(D) A statement, signed under the penalty of law, by a licensed healthcare 57
provider or licensed mental healthcare provider who treated or evaluated the decedent, stating 58
that the decedent underwent surgical, hormonal, or other treatment appropriate for the decedent 59
for the purpose of gender-affirming care, based on contemporary medical standards. 60
(4) "Gender-affirming care" shall have the same meaning as provided in section 61
102(12A) of the Human Rights Act of 1977, effective December 13, 1977 (D.C. Law 2-38; D.C. 62
Official Code § 2-1401.02(12A)). 63
(5) “Gender-diverse” means a person whose gender identity or expression is at 64
odds with what is perceived as being the gender norm in a particular context at a particular point 65
in time, including those who do not place themselves in a gender or sex binary. This includes 66 3
non-binary individuals as defined in D.C. Official Code § 1-607.61(3) and individuals who 67
identify as not cisgender. 68
(6) “Gender identity or expression" shall have the same meaning as provided 69
in section 102(12A-i) of the Human Rights Act of 1977, effective December 13, 1977 (D.C. Law 70
2-38; D.C. Official Code § 2-1401.02(12A)). 71
(7) "Personally identifiable information" shall have the same meaning as provided 72
in D.C. Official Code § 7-231.01(42) and shall also include documentation memorializing 73
transgender and gender-diverse status as defined in this chapter. 74
(5) “Transgender” shall have the same meaning as provided in D.C. Official Code § 75
1-607.61(4). 76
(6) “Transgender and gender-diverse fatality” means the death of a transgender, 77
gender-diverse, or not cisgender person by a homicide or suicide. 78
(7) “Transgender and gender-diverse mortality” means the death of a transgender, 79
gender-diverse, or not cisgender person by accident or nature. 80
Sec. 3. Establishment and duties. 81
(a) There is established a Transgender and Gender-Diverse Mortality and Fatality Review 82
Committee (“Committee”) within the Office of the Chief Medical Examiner (“OCME”). The 83
OCME shall provide facilities, staffing, and other administrative support for the Committee. 84
(b) The Committee shall evaluate transgender and gender-diverse mortalities and 85
fatalities, including associated factors: 86
(1) That occur in the District; and 87
(2) Of District residents, regardless of the place of death. 88
(c) The Committee’s duties shall include: 89 4
(1) Identifying and characterizing the scope and nature of transgender and gender-90
diverse mortalities and fatalities in the District and of District residents; 91
(2) Coordinating with other District mortality and fatality review entities to 92
minimize duplicate mortality and fatality case review; 93
(3) Describing and recording any trends, data, or patterns that are observed 94
surrounding transgender and gender-diverse mortalities and fatalities; 95
(4) Examining past events and circumstances surrounding transgender and 96
gender-diverse mortalities by reviewing records and other pertinent documents of public 97
agencies and private entities responsible for investigating transgender and gender-diverse 98
mortalities or treating transgender and gender-diverse persons; 99
(5) Performing retrospective review of socioeconomic determinant risk and 100
protective factors surrounding transgender and gender-diverse fatalities in the District; 101
(6) Developing and revising, as necessary, operating rules and procedures for 102
review of transgender and gender-diverse mortalities and fatalities, including identification of 103
cases to be reviewed, coordination among the agencies and professionals involved, and 104
improvement of the identification, data collection, and record keeping of the causes of 105
transgender and gender-diverse mortalities and fatalities; 106
(7) Recommending systemic improvements to promote improved and integrated 107
public and private systems serving transgender and gender-diverse people in the District, 108
including improved interagency coordination; 109
(8) Recommending systemic improvements to prevent and respond to transgender 110
and gender-diverse mortalities and fatalities; 111 5
(9) Recommending policies for improved access to employment, healthcare, 112
mental healthcare, housing, and educational programs for transgender and gender-diverse 113
residents; 114
(10) Creating a strategic framework for improving transgender and gender-diverse 115
health outcomes for racial and ethnic minorities in the District, including reducing disparities in 116
transgender morality and fatality rates for racial and ethnic minorities; 117
(11) Recommending training for providers who treat transgender and gender-118
diverse health patients to improve the identification, investigation, and prevention of transgender 119
and gender-diverse mortalities and, in the case of fatalities, recommending training to improve 120
the prevention of transgender and gender-diverse fatalities and to identify risk factors and 121
develop protective factors in the individual, family, and community response to violence. 122
(d)(1) By July 1 of each year, the Committee shall make publicly available and submit to 123
the Council and Mayor an annual report of its findings, recommendations, and steps taken to 124
evaluate the implementation of past recommendations, which includes the following 125
information: 126
(A) A description of the causes and contributing factors to the transgender 127
and gender-diverse mortalities and fatalities the Committee reviewed during the preceding 128
calendar year; 129
(B) A description of the state of transgender and gender-diverse health and 130
transgender and gender-diverse mortalities and fatalities in the District, including statistics and 131
causes of transgender and gender-diverse mortalities and fatalities; and 132 6
(C) Recommendations for systemic changes and legislation relating to the 133
delivery of transgender and gender-diverse health care in the District and the prevention of 134
transgender mortalities and fatalities. 135
(2) The annual report submitted pursuant to paragraph (1) of this subsection shall 136
not contain any personally identifiable information but may include aggregated data. 137
(3) If a recommendation in the annual report is directed at a particular subordinate 138
agency, the head of the subordinate agency shall respond in writing to the Committee within 30 139
days after the issuance of the annual report, describing the agency’s plans to address the 140
recommendation. 141
(4) The Chief Medical Examiner shall annually, no later than 60 days after the 142
annual report described in paragraph (1) of this subsection is made publicly available, convene a 143
symposium at which the Chief Medical Examiner shall present the report to the public, District 144
agencies implicated by the report's findings, the Deputy Mayors for Public Safety and Justice and 145
Health and Human Services, any relevant health or policy stakeholders, and the Committee's 146
representatives and members. 147
Sec. 4. Composition of the Committee; procedural requirements. 148
(a) The Mayor shall appoint one representative from each of the following District 149
agencies to serve on the Committee: 150
(1) The Office of the Chief Medical Examiner; 151
(2) The Department of Health; 152
(3) The Department of Behavioral Health; 153
(4) The Department of Health Care Finance; 154
(5) The Department of Human Services; and 155 7
(6) The Mayor’s Office of Lesbian, Gay, Bisexual, Transgender and Questioning 156
Affairs; and 157
(b) The Mayor shall additionally appoint the following members in accordance with 158
section 2(f) of the Confirmation Act of 1978, effective March 3, 1979 (D.C. Law 2-142; D.C. 159
Official Code §l-523.01(f): 160
(1) One representative from a hospital located in the District; 161
(2) One representative from a community organization specializing in 162
transgender and gender-diverse issues; 163
(3) One representative from a transgender and gender-diverse housing 164
organization; 165
(4) One representative from a transgender and gender-diverse healthcare 166
provider; 167
(5) One representative from a college or university within the District 168
conducting research in transgender and gender-diverse mortality trends or fatality prevention; 169
(6) One social worker specializing in transgender and gender-diverse issues or 170
clients; and 171
(d)(1) Members appointed pursuant to subsections (a) and (b) of this section shall serve at 172
the pleasure of the Mayor, or of the entity designating their availability for appointment. 173
(2) Members appointed pursuant to subsection (c) of this section shall serve a 3-174
year term and may be removed by the Mayor for cause. Vacancies in membership shall be filled 175
in the same manner in which the original appointment was made. 176
(e) The Committee shall select a Chairperson according to procedures set forth by the 177
Committee. 178 8
(f) The Committee shall establish quorum and other procedural requirements as it 179
considers necessary. 180
(g) No member appointed pursuant to subsection (c) of this section shall serve in a hold-181
over capacity for longer than 180 days after the expiration of the term to which they were 182
appointed. 183
(h) The Committee may invite other stakeholders to attend or present at any relevant 184
portion of a Committee meeting. 185
Sec. 5. Access to information. 186
(a) Notwithstanding any other provision of law, immediately upon the request of the 187
Committee and as necessary to carry out the Committee’s purpose and duties, the Committee 188
shall be provided, without cost and without authorization of the persons to whom the information 189
or records relate, access to: 190
(1) All information and records of: 191
(A) Any District of Columbia agency, or a District agency’s contractors, 192
including birth and death certificates, law enforcement investigation data, unexpurgated and 193
unsealed juvenile and adult criminal records, intellectual and developmental disabilities records, 194
medical examiner investigation data, autopsy reports, parole and probation information and 195
records, school records, and information records of social services, housing; and 196
(B) Health agencies that provided services to the transgender and gender-197
diverse decedent, or in the case of fatality, services provided to the decedent’s family, or an 198
alleged or suspected perpetrator of violence or abuse whose acts led to the decedent’s fatality; 199
(2) All information and records of any health-care provider, healthcare 200
facility, clinic, laboratory, or medical record department, including providers of mental health 201 9
services who provided services to the decedent, that receives information related to transgender 202
and gender-diverse mortalities. 203
(3) All information and records of any healthcare providers located in the 204
District, including providers of health and mental health services who provided services to the 205
decedent, the decedent’s family, or the alleged or suspected perpetrator whose acts led to the 206
decedent’s death; 207
(4) All information and records of any public or private child welfare 208
agency, educational facility or institution, or childcare provider doing business in the District 209
who provided services to the decedent, the decedent’s family, or the alleged or suspected 210
perpetrator whose acts led to the decedent’s death; 211
(5) Information made confidential by § 4-1302.03 or § 4-1303.06, § 7-212
231.24(n), § 7-1203.02, § 7-1305.12, §§ 16-2331, 16-2332, 16-2333, and 16-2335, and § 31-213
3426. 214
(b) The Committee may seek information from entities and agencies outside the District 215
by any legal means available to it. 216
(c)(1) Notwithstanding subsection (a)(1) of this section, information and records 217
concerning a current law enforcement investigation may be withheld, at the discretion of the 218
investigating authority, if disclosure of the information would compromise a criminal 219
investigation or prosecution. 220
(2) If information or records are withheld under paragraph (1) of this subsection, a 221
report on the status of the investigation shall be submitted to the Committee every 3 months until 222
the earliest of the following events occurs: 223 10
(A) The investigation is concluded and the information or records are 224
provided to the Committee; or 225
(B) The investigating authority determines that providing the information 226
will no longer compromise the investigation and the information or records are provided to the 227
Committee. 228
(d)(1) All records and information obtained by the Committee pursuant to subsections 229
(a) and (b) of this section pertaining to a deceased victim or any other individual shall be 230
destroyed immediately following the preparation of the Committee's annual report. All additional 231
information concerning a review, except statistical data, shall be destroyed by the Committee one 232
year after publication of the Committee's annual report. 233
(2) The Committee may have access to personally identifiable information relating 234
to transgender fatalities and mortalities; provided, that the Committee shall not disclose 235
personally identifiable information. 236
(3) The Department of Health and the Committee may retain data on facilities 237
where transgender mortalities occur for analytical purposes. 238
(e)(1) The Department of Health shall establish a procedure to identify individuals who 239
are not cisgender when reviewing decedents and to communicate said individuals to OCME on a 240
routine basis. 241
(2) The Department of Health, OCME, and any other relevant agency must use 242
their respective procedures for identifying individuals who are transgender, gender-diverse, or 243
not cisgender when reviewing decedents and communicate information about said individuals to 244
the Committee. 245 11
(A)(1) If an agency does not have such procedures already in place, they 246
will be required to establish such a procedure in writing and make it available to the public 247
within 180 days after the effective date of the “Transgender and Gender-Diverse Mortality and 248
Fatality Review Act of 2023; 249
(2) The Mayor’s Office of Lesbian, Gay, Bisexual, Transgender and 250
Questioning Affairs shall provide support to agencies in developing these procedures. 251
Sec. 6. Subpoena power. 252
(a) When necessary for the discharge of its duties, the Committee may issue subpoenas to 253
compel witnesses to appear, testify, or produce books, papers, correspondence, memoranda, 254
documents, medical records, or other relevant records. 255
(b) Except as provided in subsection (c) of this section, subpoenas shall be served 256
personally upon the witness or the witness's designated agent, not fewer than 5 business days 257
before the date the witness must appear or the documents must be produced, by a special process 258
server, at least 18 years of age, engaged by the Committee. 259
(c) If, after a reasonable attempt, personal service on a witness or a witness's agent cannot 260
be effected, a special process server identified in subsection (b) of this section may serve a 261
subpoena by registered or certified mail not fewer than 8 business days before the date the 262
witness must appear, testify, or produce documents. 263
(d) If a witness who has been personally summoned neglects or refuses to obey the 264
subpoena issued pursuant to subsection (a) of this section, the Committee may report that fact to 265
the Superior Court of the District of Columbia, and the court may compel obedience to the 266
subpoena to the same extent as witnesses may be compelled to obey the subpoenas of the court. 267
Sec. 7. Confidentiality of information and proceedings. 268 12
(a) Except as provided in this section, information and records obtained or created by the 269
Committee are confidential and not subject to civil discovery or to disclosure pursuant to 270
subchapter II of Chapter 5 of Title 2. 271
(b) Information and records presented to the Committee for review shall not be immune 272
from subpoena, discovery, or prohibited from being introduced into evidence solely because they 273
were presented to or reviewed by the Committee if the information and records have been 274
obtained through other sources. 275
(c) Information required to be reported under §4-1321.02 or §4-1321.03, shall be 276
disclosed by the Committee to the Child and Family Services Agency. 277
(d) A person other than a Committee member who appears before or participates in the 278
Committee's review of fatalities shall sign a confidentiality agreement acknowledging that any 279
information provided to the Committee is confidential; provided, that any such confidentiality 280
agreement shall account for situations where disclosure is necessary for the person to comply 281
with a request for information from the Committee. 282
(e) Committee meetings shall be subject to subchapter IV of Chapter 5 of Title 2, except 283
that Committee meetings shall be closed when the Committee is discussing cases of individual 284
transgender fatalities and mortalities or where the identity of any person, other than a person who 285
has expressly consented to be identified, can be ascertained. 286
(f) In the case of fatality, information identifying a victim of a fatality or that victim’s 287
family members, or an alleged perpetrator of the fatality, shall not be disclosed in any report that 288
is available to the public. 289
(g) The Committee may disclose information to other entities when the Committee 290
determines that disclosure is necessary to carry out the Committee's purpose and duties. The 291 13
Committee may disclose Committee records to another District fatality or mortality review 292
committee or board at the request of the District fatality or mortality review committee or board, 293
if the other District fatality or mortality review committee or board is governed by confidentiality 294
that is substantially similar to the confidentiality by which the Committee is governed. 295
(h) This section shall not be construed to prohibit a person from: 296
(1) Disclosing information that the person obtained independently of the 297
Committee; or 298
(2) Disclosing information that is already public. 299
Sec. 8. Immunity from liability for providing information to the Committee. 300
(a) Any person, hospital, or institution participating in good faith in providing 301
information to the Committee pursuant to this chapter shall have immunity from administrative, 302
civil, or criminal liability that might otherwise be incurred or imposed with respect to the 303
disclosure of the information. In any such proceeding, there shall be a rebuttable presumption 304
that the person, hospital, or institution that provided information to the Committee acted in good 305
faith. 306
(b) If acting in good faith, without malice, and within the parameters of the operating 307
rules and procedures established by this chapter, members of the Committee are immune from 308
civil liability for an activity related to reviews of transgender mortalities and fatalities, as the 309
term is defined in §5-1431.01(e). 310
Sec. 9. Unlawful disclosure of information; penalties. 311
Whoever knowingly discloses, receives, makes use of, or permits the use of information 312
concerning a victim or person in violation of this chapter shall be subject to a civil fine of not 313 14
more than $1,000. Violations of this chapter shall be prosecuted by the Office of the Attorney 314
General or the Attorney General’s designee in the name of the District of Columbia. 315
Sec. 10. Rules. 316
The Mayor, pursuant to subchapter I of Chapter 5 of Title 2, may issue rules to 317
implement the provisions of this chapter. 318
Sec. 11. Section 303(a) of the Prevention of Child Abuse and Neglect Act of 1977, 319
effective September 23, 1977 (D.C. Law 2-22; D.C. Official Code § 4-1302.03(a)), is amended 320
as follows: 321
(a) Paragraph (10) is amended by striking the phrase “; and” and inserting a semicolon in 322
its place. 323
(b) Paragraph (11) is amended by striking the period and inserting the phrase “; and” in 324
its place. 325
(c) A new paragraph (12) is added to read as follows: 326
“(12) The Transgender and Gender-Diverse Mortality and Fatality Review 327
Committee, for the purpose of examining past events and circumstances surrounding transgender 328
mortalities and fatalities, as that term is defined in section XX of the Transgender and Gender-329
Diverse Mortality and Fatality Review Committee Amendment Act of 2023, passed on 2
nd
330
reading on XXX, 2023 (Enrolled version of Bill XX-XXX). The Transgender and Gender-331
Diverse Mortality and Fatality Review Committee shall be granted, upon request, access to 332
information contained in the files maintained on any deceased child or on the parent, guardian, 333
custodian, kinship caregiver, day-to-day caregiver, relative/godparent, caregiver, or sibling of a 334
deceased child.”. 335 15
Sec. 12. Section 306(a) of the Prevention of Child Abuse and Neglect Act of 1977, 336
effective October 18, 1979 (D.C. Law 3-29; D.C. Official Code §4-1303.06(a)), is amended as 337
follows: 338
(a) Paragraph (5) is amended by striking the phrase “; or” and inserting a semicolon in its 339
place. 340
(b) Paragraph (6) is amended by striking the period and inserting a semicolon in its 341
place. 342
(c) Paragraph (7) is amended by striking the period and inserting “; or” in its place. 343
(d) A new paragraph (8) is added to read as follows: 344
“(8) The investigation or review of transgender and gender-diverse mortalities and 345
fatalities, as that term is defined in section XX of the Transgender and Gender-Diverse Mortality 346
and Fatality Review Committee Amendment Act of 2023, passed on 2
nd
reading on XX X, 2023 347
(Enrolled version of Bill XX-XXX).”. 348
Sec. 13. Title 16 of the District of Columbia Official Code is amended as follows: 349
(a) Section 16-311 is amended by striking the phrase “Child Fatality Review Committee 350
or the Violence Fatality Review Committee" and inserting the phrase “Child Fatality Review 351
Committee, Violence Fatality Review Committee, or Transgender and Gender-Diverse Mortality 352
and Fatality Review Committee” in its place. 353
(b) Section l6-2332(c)(g) is amended as follows: 354
(1) Subparagraph (D)(ii)(II) is amended by striking “; and” and inserting a 355
semicolon in its place. 356
(2) Subparagraph (E) is amended by striking the period and inserting “; and” in its 357
place. 358 16
(3) A new paragraph (F) is added to read as follows: 359
“(F) The Transgender and Gender-Diverse Mortality and Fatality Review 360
Committee for the purposes of examining past events and circumstances surrounding transgender 361
fatalities, as that term is defined in section XX of the Transgender and Gender-Diverse Mortality 362
and Fatality Review Committee Amendment Act of 2023, passed on 2
nd
reading of XX X, 2023 363
(Enrolled version of Bill XX-XXX), or for the discharge of its official duties.”. 364
(c) Section 16-23331(c) is amended as follows: 365
(1) Subparagraph (E) is amended by striking “; and” and inserting a semicolon in 366
its place. 367
(2) Subparagraph (F) is amended by striking “; and” and inserting a semicolon in 368
its place. 369
(3) A new subparagraph (G) is added to read as follows: 370
(G) The Transgender and Gender-Diverse Mortality and Fatality Review 371
Committee when necessary for the discharge of its official duties; and” 372
(d) Section 16-2335(d) is amended by striking the phrase “Child Fatality Review 373
Committee and the Violence Fatality Review Committee” and inserting the phrase “the Child 374
Fatality Review Committee, the Violence Fatality Review Committee, and the Transgender and 375
Gender-Diverse Mortality and Fatality Review Committee” in its place. 376
Sec. 6. Section 204(d)(3) of the Freedom of Information Act of 1976, effective March 29, 377
1977 (D.C. Law 1-96; D.C. Official Code § 2-534(d)), is amended as follows: 378
(a) Subparagraph (C) is amended by striking the phrase “; and” and inserting a 379
semicolon in its place. 380 17
(b) Subparagraph (D) is amended by striking the period and inserting “; and” in its 381
place. 382
(c) A new subparagraph (E) is added to read as follows: 383
“(E) The Transgender and Gender-Diverse Mortality and Fatality Review 384
Committee, established by section XX of the Transgender and Gender-Diverse Fatality Review 385
Committee Amendment Act of 2023, passed on 2
nd
reading of XX X, 2023 (Enrolled version of 386
Bill XX-XXX).”. 387
Sec. 7. Section 2(f) of the Confirmation Act of 1978, effective March 3, 1979 (D.C. Law 388
2-142; D.C, Official Code § 1-523.01(1)), is amended as follows: 389
(a) A new paragraph (72) is added to read as follows: 390
“(72) The Transgender and Gender-Diverse Mortality and Fatality Review 391
Committee, established by section 102(b) of the Fatality Review Committee Amendment Act of 392
2023, passed on 2
nd
reading on XX X, 2023 (Enrolled version of Bill XX-XXX).”. 393
Sec. 8. Fiscal impact statement. 394
The Council adopts the fiscal impact statement in the committee report as the fiscal 395
impact statement required by section 4a of the General Legislative Procedures Act of 1975, 396
approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a). 397
Sec. 9. Effective date. 398
This act shall take effect following approval by the Mayor (or in the event of veto by the 399
Mayor, action by Council to override the veto), a 30-day period of congressional review as 400
provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 401
24, 1973 (87 Sat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of 402
Columbia Register. 403 18
404
405